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Abstract
Aim: The authors give a complete overview on this disease from epidemiology to treatment.
Background: Cholangiocarcinoma (CCA) is an epithelial tumor with features of cholangio-
cyte differentiation. Most patients suffer from a nonresectable disease since presentation 
and the exitus occurs within 12 months from diagnosis. Biliary epithelial carcinogenesis 
is a multistep process that involves the transition from hyperplasia to dysplasia to car-
cinoma. The clinical approach should be multidisciplinary, and the diagnosis should be 
considered when there is a histological finding of adenocarcinoma without any other evi-
dences of an extrahepatic primitive neoplasia. Surgical resection with histologically nega-
tive margins is the only curative treatment. Nevertheless for unresectable patients, there 
are several other approaches: systemic chemotherapy is the widely used treatment, but a 
large proportion of patients could be suitable for liver-directed therapies. These options 
include transarterial chemoembolization (TACE), radioembolization (TARE), hepatic arte-
rial infusion (HAI), percutaneous ablation, and external beam radiation therapy (EBRT).
Conclusion: Intrahepatic cholangiocarcinoma is a relatively rare disease with a poor prog-
nosis. Diagnosis is based on imaging, but pathological anatomy plays an important role. 
Surgery is still the gold standard treatment; nevertheless, unresectable patients could be 
treated in a multimodality strategy with a significant improvement in terms of survival.
Keywords: cholangiocarcinoma, chemotherapy, surgery
1. Introduction
The first description of a case of cholangiocarcinoma dates from 1840 on the merits 
of Durand-Fardel. Cholangiocarcinoma (CCA) is an epithelial tumor with features of 
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cholangiocyte differentiation [1]. It originates from the ductal epithelium of the biliary tree 
from the canals of Hering to the main bile duct [2]. This pathology is sordid, difficult to 
diagnose, and is generally fatal because of late clinical presentation and lack of effective 
alternative therapeutic approaches to surgery. Most patients suffer from a nonresectable 
disease since presentation and the exitus occurs within 12 months from diagnosis for the 
effects of cachexia and rapid decline in performance status. Liver failure, recurrent sepsis, 
and secondary biliary obstruction can also contribute to the high mortality [3]. The overall 
survival rate, including patients undergoing surgery, is low, with less than 5% of patients 
alive at 5 years. Although cholangiocarcinoma is a relatively rare disease, the interest of the 
scientific community has increased in recent years also due to the augmented incidence of 
the intrahepatic variant [3].
2. Epidemiology
CCA represents 3% of all gastrointestinal tumors and is the second most common primi-
tive liver cancer. The incidence peak is reached in the seventh decade and is slightly more 
frequent in the male with a ratio of 1.5:1 [4]. The rates of incidence are characterized by an 
enormous geographical variation reflecting the distribution of local environmental risk fac-
tors in addition to the genetic differences between the various populations [5, 6]. The increase 
in incidence rates along with mortality rates has been documented worldwide: Europe and 
North America, Japan, and Australia [3]. Consistent with the data from US registers [7], the 
AISF “Cholangiocarcinoma” committee reported comprehensive national data from Italian 
National Cancer Registries of the period between 1988 and 2002. A consistently increasing 
trend was observed for iCCA: from 5 to 12 cases per million (average increase = 6% per year) 
[8]. In the United Kingdom, since the 1990s, the iCCA exceeded hepatocellular carcinoma as 
the leading cause of death among primitive liver tumors [9].
3. Prognosis
The overall prognosis is poor with a 5-year survival rate of less than 5%. The median sur-
vival for iCCA is between 18 and 30 months, but if not resectable it decreases to 6 months. 
The only curative therapeutic option may be expected from liver resection for tumors at 
the initial stage, after which 5-year survival rate varies from 20 to 40% [10]. However, as 
most patients present with an advanced disease, thus precluding the surgical option, 75% 
of patients die between the first year from diagnosis [11]. Cancer cachexia, liver failure, and 
recurrent sepsis due to biliary obstruction are among the main causes of mortality. Although 
the 1-year survival has increased over time, from 16% in 1975–1979 to 28% in 1995–1999, the 
5-year survival, by contrast, has not shown any significant change [11]. Globally, hepatobili-
ary malignancies account for 13% of cancer-related deaths; 10–20% of these are attributable 
to CCA [1].
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4. Classification
CCA may arise from biliary epithelium in each portion of the biliary system. According 
to the staging of the American Joint Committee on Cancer (AJCC) [12] and the Union for 
International Cancer Control (UICC) system [13], CCA is classified according to its anatomi-
cal location as intrahepatic (iCCA), perihilar (pCCA), and distal CCA (dCCA). In a large series 
of patients with bile duct cancer, 8% had iCCA, 50% had pCCA, and 42% had dCCA [14].
Based on the classification of the Liver Cancer Study Group of Japan, iCCA can be classi-
fied by macroscopic growth patterns as mass-forming (MF-iCCA), periductal infiltrating 
(PI-iCCA), and intraductal growing iCCA (IG-iCCA) [2]. iCCAs are highly heterogeneous 
tumors and several classifications have been proposed [15–18]. Two types of candidate 
stem/progenitor cells of the biliary tree are considered to exist at the peribiliary glands 
for large bile ducts and at the canals of Hering for small ducts [19, 20]. Mucin-producing 
cells of segmental biliary ducts may give rise to tubular adenocarcinoma producing mucin 
with or without micropapillary structures [21]. Instead, iCCA originating from the ductular 
epithelium may exhibit mixed characteristics between hepatocellular and cholangiocellular 
carcinoma. In fact, bile ducts are composed of progenitor liver cells capable of differentiat-
ing both hepatocytes and cholangiocytes [22]. The mixed iCCA type (bile ductular) is fre-
quently associated with chronic liver diseases (viral hepatitis or cirrhosis). The mucinous 
iCCA (bile duct) is more frequently associated with primary sclerosing cholangitis (PSC) 
[23]. The mass-forming type iCCA is characterized by a well-defined and lobulated mass 
with a various degree of sclerotic change of the tumor center in the liver parenchyma. When 
iCCA arises in a cirrhotic liver or is small sized, it exhibits an ill-defined tumor border. 
Necrotic or hemorrhagic changes can be recognized in larger MF-iCCA. The longitudinal 
extension along the large bile ducts is peculiar of the periductal infiltrating type. Dilation 
of the peripheral bile ducts and cholestasis are evident when biliary stenotic changes occur. 
The proliferation within the lumen of large bile ducts is characteristic of the intraductal 
growth type. This type shares the features of intraductal papillary neoplasms of the bile 
duct [16].
5. Risk factors
5.1. Primitive sclerosing cholangitis
Primitive sclerosing cholangitis (PSC) is the best-known predisposing condition in Western 
countries. The cumulative annual risk is 1.5% after the onset of jaundice and the prevalence 
of cholangiocarcinoma is between 8 and 40% [3]. A Dutch epidemiological study showed that 
the risk of CCA in patients with PSC was 9% at 10 years from diagnosis, and patients with a 
concomitant inflammatory bowel disease (IBD) presented a risk at 10 and 20 years, respec-
tively, of 14 and 31%, significantly higher than patients without IBD, 2% at 10 and 20 years 
(p = 0.008) [24]. Predictive prognostic factors of CCA onset are sudden and progressive 
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jaundice, unintended weight loss, biliary dilatation proximal to the stenosis, CA 19-9 increase 
over 100 U/mL, and cell dysplasia on bile duct cytological brushing [24].
5.2. Parasitic infections
Numerous experimental and epidemiological data suggest the association between hepatic 
parasitic infestation by Opisthorchis viverrini or Clonorchis sinensis, the so-called oriental cholangi-
opathies and the CCA [3], whose eggs released in the guest biliary system accumulate progres-
sively causing chronic inflammation and therefore increasing the risk of CCA development [11].
5.3. Fibropolycystic liver disease
Congenital malformations of the biliary tree associated with Caroli disease, congenital hepatic 
fibrosis and coledochal cysts are responsible for 15% risk of developing a cholangiocarcinoma 
after the second decade, at an average age of 34 years. The overall incidence of this neoplasia 
in patients with untreated cysts is 28% [25]. Bile duct adenomatosis and biliary papillomatosis 
are also associated with the development of CCA [3].
5.4. Intrahepatic biliary stones
Hepatolithiasis is rare in Western countries but relatively common in some regions of Asia, 
and in 10% of the affected patients, it is responsible for the development of iCCA [26].
5.5. Exposure to chemical carcinogens
Numerous chemical compounds have been suspected to induce CCA. Thorotrast, a radioac-
tive contrast medium based on Torus dioxide, requires a special mention. Broadly used in 
radiology between 1920 and 1950, it has been shown to be responsible for increasing the risk 
of CCA by 300 times in the general population [27, 28]. Several minor studies have identified 
other carcinogenic chemicals such as asbestos, vinyl chloride, nitrosamines, isoniazid, and 
first-generation oral contraceptives [29].
5.6. Viral hepatitis
The risk of developing a CCA on a cirrhotic liver is 10 times greater than the general popula-
tion: 0.7 versus 10.7% [30]. A Korean case-control study showed that 12.5% of CCA patients 
were positive for C virus (HCV) and 13.8% were positive for the surface antigens of hepatitis 
virus B (HBsAg) compared with 3.5 and 2.3% of controls [31]. In 2000, a prospective Japanese 
study reported that the risk of developing CCA in HCV patients was 3.5% at 10 years, 1000 
times greater than the risk of the general population [32]. A large US epidemiological study 
has shown that HCV infection is a risk factor for iCCA (hazard ratio: 2.55; IC 95%: 1.3–4.9) but 
not for the extrahepatic variant (hazard ratio: 1.5; IC 95%: 0.6–1.85) [33]. Although the human 
immunodeficiency virus (HIV) does not cause cirrhosis by itself, 0.5% of infected patients 
developed a CCA as compared to 0.1% of controls, confirming previous observations that 
chronic viral infections can predispose to the neoplastic transformation of some cell lines [34].
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6. Prevention and screening
For patients with PSC, brush cytological examination or biopsy may be used as a surveil-
lance tool for the early detection of cellular atypia. In high-risk areas, where liver infec-
tion is endemic, prevention of cholangiocarcinoma may be achieved by early treatment of 
infection.
7. Pathogenesis
Biliary epithelial carcinogenesis is a multistep process that involves the transition from 
hyperplasia to dysplasia to carcinoma. Chronic inflammation, cell damage, and bile flow 
obstruction lead to chronic exposure of cholangiocytes to the carcinogenetic action of bili-
ary components. The bile of patients with biliary inflammatory diseases contains increased 
levels of oxysterols, oxygenated cholesterol derivatives, which can promote carcinogenesis 
by inducing COX-2 expression, EGF (epidermal growth factor receptor) transactivation, 
by suppressing E-cadherin, and blocking the degradation of Mcl-1 (myeloid cell leukemia 
protein 1) [35]. The neoplastic transformation of the biliary epithelium is accompanied by 
numerous molecular and genetic alterations. Abnormal cell proliferation and survival are 
induced by the activation of autonomous growth factors such as HGF/Met, IL-6, ErbB2, 
K-ras, BRAF, and COX-2. Alterations in the DNA repair mechanisms, such as microsatellite 
instability, increase the risk of genetic damage. Immortalization of biliary cells is mediated 
by the modulation of telomerase activity and by the inactivation of numerous oncosuppres-
sor genes. For example, inactivating mutations or loss of heterozygosity (LOH) of p53 (occur-
ring from 20 to 70% in CCA cells), hypermethylation of the promoter with the inactivation 
of p16, and increased cyclin D1 are among the more responsible for the deregulation of the 
cell cycle. In addition, the hyperexpression of anti-apoptotic proteins, such as Bcl-2, Bcl-xl, 
and Mcl-1, is responsible for the alteration of programmed death mechanisms. Eventually, 
invasion and metastases are favored by the loss of E-cadherin and catenins. Angiogenesis 
is promoted by VEGF, COX-2, and TGFβ1 [35]. Calcium S100A4 binding protein, normally 
expressed at a cytoplasmic level in the epithelial cells and at a nuclear level in mesenchymal 
cells, is increased in those cells who underwent neoplastic transformation, thus identifying 
a CCA subtype that responds significantly less to surgical therapy [36].
8. Tumor stroma and tumoral progression
Carcinogenesis has been recognized as a multi-step process during which cancerous cells 
accumulate multiple and consecutive genetic alterations. Only in recent years, tumor progres-
sion has been recognized as the product of a dynamic crosstalk between the various cells 
of tumor parenchyma and the surrounding tissue, the tumor stroma [37]. The interaction 
between parenchymal cells and the stromal microenvironment can largely determine the 
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tumor phenotype [38]. Invasive carcinomas are often associated with the expansion of the 
tumoral stroma and increased extracellular matrix deposition [39]. Cancer cells can modify 
the adjoining stroma to create a permissive and supportive microenvironment that supports 
tumor growth.
Knowledge and control of the tumor microenvironment is becoming as important as that of cancer 
cells in understanding biology and in defining new therapeutic approaches [40]. Morphological 
evidences describe it as a “desmoplastic” reaction that contains many cell types [41]. Endothelial 
cells, tumor-associated macrophages, and cancer-associated fibroblasts (CAFs) promote tumor 
growth and progression. CAFs are large elongated mesenchymal cells whose characteristic immu-
nohistochemical markers are Alpha Smooth Muscle Actin (α-SMA), Fibroblast Activation Protein 
(FAP), Thy-1, Desmin, and Protein S100A4 [42, 43]. CAFs can derive from quiescent fibroblasts, 
epithelial cells through epithelial-mesenchymal transition (EMT), medullary mesenchymal cells, 
or endothelial cells [44]. In the scenario of tumor growth, CAF secretes and synthesizes type I 
and IV collagen, fibronectin, proteoglycan, heparan sulfate, connective tissue growth factor, and 
plasminogen activator. Moreover, CAFs are an important source of proteases that degrade the 
extracellular matrix (ECM) as MMPs (metalloproteinases) that play an important role in tumori-
genesis [45]. Recruitment and accumulation of CAFs in tumor stroma allow these cells to actively 
communicate with inflammatory, tumor, epithelial, endothelial, and peripheral cells through 
the secretion of numerous growth factors, cytokines, and chemokines (TGFβ, PDGF, and HGF) 
that play a role in the initiation of tumor progression [46–49]. The stroma of cholangiocarcinoma 
undergoes profound changes in its composition during cholangiocarcinogenesis with an upregu-
lation of genes related to the cell cycle, extracellular matrix, TGFβ pathway, and inflammation [50, 
51]. The desmoplastic stroma of intrahepatic cholangiocarcinoma is often rich in positive αSMA 
fibroblasts surrounding the ducts, glandular structures, and neoplastic cholangiocyte aggregates 
(Figure 1). Patients with iCCA having a desmoplastic reaction rich in positive αSMA-CAF have 
a significantly lower overall survival and a disease-free survival than iCCAs with αSMA lower 
levels [52]. For example, a study by Chuaysri et al. reported a significantly higher αSMA expres-
sion in tumors larger than 5 cm, and survival analysis in 52 patients with 5-year follow-up shows 
that 31 patients with higher levels of αSMA present 6% survival than 29% of patients with lower 
expression levels (p = 0.013) [53].
Cell survival and resistance to chemotherapy are mediated by periostin, PDGF-BB, sphin-
gosine-1-phosphate (S1P), and prostaglandin E2 by activating the Akt/PKB pathway. The 
Figure 1. Alpha-SMA expression in normal liver parenchyma (in brown, a) and in cholangiocarcinoma specimen at 
immunohistochemistry (b) and at immunofluorescence (in red, c), personal series.
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action on the extracellular matrix (ECM) of CAFs is mediated by the activation of different 
metalloproteinases (MMP-1, -2, -9) and secretion of various profibrotic proteins such as TGFβ, 
PDGF-B, connective tissue growth factor (CTGF), SDF-1, angiotensin II, and IGFBP-5/-7 (insu-
lin growth factor-binding protein-5/-7) [54].
9. Clinical features
Rarely, cholangiocarcinoma occurs in subjects under 40 years of age and the characteristic 
signs of presentation depend on the location along the biliary tree. The lesions at the biliary 
bifurcation or at the distal common bile duct present with the sequelae of biliary obstruc-
tion: jaundice, clay-colored stools, and dark urine. Peripheral tumors, which originate from 
the intrahepatic ducts, tend to occur with nonspecific symptoms such as malaise, weight 
loss, abdominal pain, hepatomegaly, right upper abdominal mass, and fever. Cholangitis 
is an atypical presentation mode. However, in general, the disease remains silent until an 
advanced stage. In fact, iCCAs are incidentally diagnosed in up to 12–30% of patients and 
are asymptomatic in up to 30–73% of all diagnosed cases. This nonspecific and aggres-
sive behaviour leads to the reported unresectability at presentation in half of all patients 
[55–57].
10. Diagnosis
Diagnostic confirmation can be made difficult by the wide spectrum of alternative diagnoses 
including benign pathologies (iatrogenic lesions, PSC and choledocholithiasis) and other can-
cers such as gall bladder cancer and ab extrinseco compression. The clinical approach should 
be multidisciplinary, and the diagnosis of intrahepatic CCA should be considered when there 
is an histological finding of adenocarcinoma without any other evidences of an extrahepatic 
primitive neoplasia.
11. Diagnostic procedures
11.1. Serologic tests
Serologic tests are characterized by the nonspecific elevation of serum bilirubin and 
liver enzymes, alkaline phosphatase, γ-glutamyltranspeptidase and less commonly trans-
aminases. There are no cancer-specific markers for cholangiocarcinoma. The most commonly 
used are CA19-9 and CEA, but the optimal cut-off level for suspicion of cholangiocarcinoma 
is not known [58]. Their diagnostic utility is limited due to their low sensitivity (50–63% and 
15–68%, respectively). Ca 19-9 can be significantly elevated in other malignancies and in 
inflammatory and infectious conditions. Furthermore, up to 10% of the population shows 
a Lewis-negative blood-group phenotype, thus resulting in an unuseful marker [59]. After 
curative resection, both serum levels decrease from a preoperative level.
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11.2. Radiological techniques
Abdominal ultrasound is the first level survey. It reaches a sensitivity and a specificity of 89 and 
95%, respectively, in confirming the dilatation of intrahepatic biliary ducts, locating the site 
of obstruction, and excluding the presence of lithiasis [4]. The mass-forming subtype usually 
appears as a homogeneous, hypoechoic lesion, while the periductal infiltrating subtype pres-
ents as a small mass-like lesion or as a diffuse biliary tract thickening. However, ultrasound is 
limited because of nonspecific findings, and therefore, it is not capable of differentiating the 
nature of the lesion (iCCA, HCC, metastases). If a suspect lesion is detected by ultrasonogra-
phy, further cross-sectional imaging is required for confirmation [60, 61] (Figure 2a–c).
Computed tomography (CT) is highly susceptible to determining intrahepatic neoplastic lesions 
of at least 1 cm in diameter, locating the site of biliary obstruction and the presence of lymph-
adenopathy [3]. ICCA may present with central diffuse hypoenhancement due to fibrotic 
Figure 2. Mass-forming intrahepatic cholangiocarcinoma. (a–c) Abdominal ultrasound confirming the dilatation of 
intrahepatic biliary ducts, locating the site of obstruction. It appears as a homogeneous, hypoechoic lesion. (d–f) CT 
scan, the lesion is hypoenhanced, with capsular retraction and biliary dilatation. Right portal vein invasion can be noted. 
(g–i) MRI is characterized by peripheral enhancement followed by progressive centripetal filling.
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remodeling, capsular retraction caused by liver atrophy (21–36% of all cases), dilated bile 
ducts distal to the mass, or satellite nodules [60] (Figure 2d–f).
Magnetic resonance imaging (MRI) is the gold standard, with diagnostic potential greater than 
CT with 88% sensitivity and 95% specificity. In addition to identifying intraepithelial lesions, 
it allows to create three-dimensional reconstructions of the biliary tree (cholangiopancreatog-
raphy phases) allowing the evaluation of the upstream and downstream biliary ducts and it 
determines the extent of biliary invasion, vessel infiltration, local lymphadenopathy, and dis-
tant metastases [4]. ICCAs appear hypointense on T1-weighted images and heterogeneously 
hyperintense on T2-weighted images with a central hypointensity due to fibrotic remodel-
ing and necrosis in mass-forming subtypes. The contrast-enhanced MRI is characterized by 
peripheral enhancement followed by progressive centripetal filling and contrast pooling on 
delayed images [62] (Figure 2g–i).
Positron emission tomography (PET)-CT with deoxy-fluoroglucose is able to identify neoplastic 
lesions of the bile ducts >1 cm in diameter, although it is less useful in evaluating infiltrating 
masses [4]. Its diagnostic value is controversial. In evaluating MF-iCCAs, it has a sensitivity of 
about 85–94%, but the sensitivity in other subtypes is poor (18%) [62]. However, some studies 
revealed that PET-CT was able to detect occult metastases in 20–30% of all patients, which 
have not been identified by CT or MRI [61].
11.3. Pathological diagnosis
Making a tissue diagnosis of cholangiocarcinoma is not easy because of its location, size, and 
desmoplastic characteristics. Bile cytology can be obtained with fine needle aspiration with 
ultrasound or CT guidance; brush cytology can be obtained with ERCP or an endoscopic 
ultrasound-guided fine needle aspiration (EUS-FNA). Adenocarcinoma is the most common 
histological findings in iCCA and can be difficult to distinguish from metastatic adenocarci-
nomas. Immunohistochemical (IHC) evaluation may improve its accuracy. ICCA diagnosis is 
suggested by TTF1 (lung), CDX2 (colon), and DPC4 (pancreas) negative findings, while AE1/
AE3, CK7, and CK20 positive findings suggest the biliary origin of the disease. Liver biopsy in 
non-cirrhotic patients candidate to a curative resection is not required due to the risk of tumor 
spread and hemorrhage [59, 62].
11.4. Additional assessment
Depending on the fact that secondary metastasis is more frequent than iCCAs, a careful 
evaluation is needed to rule out other primary malignancies. This should include: chest X-ray, 
esophagogastroduodenoscopy (EGDS), and colonoscopy. In women, a gynecologic evalua-
tion and a mammography should be performed.
12. Clinical staging
Currently, there is no consensus regarding a staging system for iCCA [21, 63]. Individual 
staging systems for iCCA had previously been proposed by the National Cancer Center 
of Japan (NCCJ) staging system by Okabayashi et al. [64], and Yamasaki proposed a stag-
ing system based on the Liver Cancer Study Group of Japan (LCSGJ) [65]. However, these 
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Figure 3. Treatment flowchart.
staging systems were never validated and widely used in the Western countries. Given the 
lack of a proposed staging system in the West, Nathan et al. [66] analyzed the Surveillance, 
Epidemiology, and End Results database (SEER database) aimed at developing a staging 
system for iCCA. In 2010, the seventh edition of AJCC/UICC staging manual adopted most 
of the recommendations from the staging system proposed by Nathan et al. and published 
the first unique staging system for ICC. The new classification focuses on multiple tumors, 
vascular invasion, and lymph node metastasis. The eighth edition has been recently pub-
lished with several notable changes to the T-category classification schema. The 8th edition 
introduces T1a and T1b subgroups, which discriminate the T1 group based on the cut-off 
of 5 cm. Periductal invasion is removed from the T4 category, which is now defined as the 
direct invasion of local extrahepatic structures, also classified as Stage IIIB (previously Stage 
III). Nodal staging is defined by the minimum recover y of six lymph nodes. Subsequently, 
Spolverato et al. [67] published a comparative performance analysis between the 7th and 8th 
edition demonstrating that the revised edition can better stratify the risk of death of Stage III 
and T3 patients (Figure 3).
13. Surgical management
13.1. Preoperative evalutation
Postresection liver failure (PLF) remains the most important factor associated with postopera-
tive mortality after major liver resections (resection of 4 or more Couinaud liver segments) 
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[68–70]. Prevention of this severe and often lethal complication is attempted through a careful 
preoperative liver evaluation. In our center, the liver function is determined by the combined 
analysis of volumetric liver assessment, liver functional MRI, and the indocyanine green 
clearance retention test.
13.1.1. Volumetric liver analysis
A CT- or MRI-based volumetric liver analysis is performed to determine total liver volume 
(TLV) and future remnant liver volume (FRLV), and remnant liver volume percentage (RLV%) 
is then calculated. In patients with healthy livers, approximately 25% of the liver parenchyma 
needs to be preserved to prevent PLF. In damaged, post-chemotherapy or cirrhotic livers, up 
to 50% liver parenchyma needs to be spared [71–74] (Figure 4).
13.1.2. MRI-based segmental liver function
MRI-based T1 relaxometry with the liver-specific contrast agent gadolinium-ethoxybenzyl 
diethylenetriaminepentaacetic acid (Gd-EOB-DTPA) is a useful method for assessing over-
all and segmental liver function [75]. Gd-EOB-DTPA is a hepatocyte-specific MRI contrast 
agent. Due to its hepatocyte-specific uptake and paramagnetic properties, functioning areas 
of the liver exhibit shortening of the T1 relaxation time. Reduced liver function correlates with 
decreased Gd-EOB-DTPA accumulation in the hepatocytes during the hepatobiliary phase.
13.1.3. Indocyanine green clearence test
Indocyanine green retention rate at 15 minutes (ICG-R15) has been widely used as a routine 
guideline in Eastern countries for making appropriate surgical decisions in hepatocellular 
carcinoma patients, and recent evidence suggests that ICGR-15 is applicable to Western popu-
lations for evaluating preoperative liver function. The ICG clearance test is performed by 
Figure 4. Volumetric liver analysis. It is performed to determine total liver volume (TLV) and future remnant liver 
volume (FRLV) and remnant liver volume percentage (RLV%).
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administering intravenously a dose of 0.5 mg/kg ICG. The ICG plasma disappearance rate 
(PDR) is then measured transcutaneously using a near-infrared finger clip sensor. The ICG 
retention rate at 15 minutes (R15) is then calculated. The ICG retention value at 15 minutes 
(ICG R15) after injection is approximately 10% in normal persons, and this value is used for 
stratification of patients [76, 77].
Patients eligible for surgery should have a good performance status. Albumin and bilirubin 
level are predictors of the risk of PLF. In 1996, Su et al. published the results of a multivariate 
analysis which disclosed that an adequate nutritional support to increase serum albumin over 
3 g/dL is the most important factor to decrease postoperative mortality and that total bilirubin > 
or = 10 mg/dL is associated with poorer survival [78]. As such, preoperative management 
should include biliary drainage (endoscopic or percutaneous) and portal vein embolization 
in patients with obstructive jaundice or with an insufficient remnant liver volume percentage, 
respectively.
13.2. Surgery
Surgical resection with histologically negative margins is the only curative treatment for iCCA. R0 
resection rates can approach 85% with an aggressive surgical approach that often involves a 
major/extended hepatectomy and vascular and bile duct resection (Figure 5). The size, the loca-
tion of the lesion, and the degree of tumor infiltration determine the extent of resection. The 5-year 
overall survival (OS) rate is null in patients with positive margins and almost 40% with negative 
margins. Indeed, aggressive surgical strategies are vital for long-term survival. Unfortunately, 
only few patients are candidates for surgery, and therefore, the surgeon must be involved from 
the beginning in the diagnostic path to ensure an early approach [29, 57, 79]. Positive tumor 
margins, lymph node metastases, cirrhosis, especially advanced cirrhosis with Child-Pugh score 
beyond A, and presence of portal hypertension are associated with poor outcomes in surgical 
cohorts [57, 80]. In patients with bilateral, multifocal, or multicentric disease, resection should 
be avoided. Contemporary studies do not support the option of liver transplantation for intra-
hepatic cholangiocarcinoma unlike for selected patients with perihilar cholangiocarcinoma [81]. 
Staging laparoscopy, whose role has not yet been fully elucidated, could be useful in the 
Figure 5. Intrahepatic CCA. (a) Left hepatectomy, biliary resection, and bilioenteric anastomosis with right anterior bile 
duct S5/8, right posterior bile duct S6/7, and segmental S1 bile duct and (b) left lateral sectionectomy.
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assessment of peritoneal implants. The 2015 Consensus on iCCA stated that it should be uti-
lized in high-risk patients (multicentric disease, high CA 19-9, questionable vascular invasion, 
or suspicion of peritoneal disease) [62]. The 2015 expert consensus on iCCA stated that lymph-
adenectomy should always be performed as part of the standard surgical treatment due to the 
high incidence of node metastasis and its prognostic importance. Even though the incidence of 
nodal metastasis is high, reaching 40% in some studies, data from the National Cancer Institute’s 
Surveillance, Epidemiology and End Results (SEER) registry show that only 55% of patients have 
pathologic evaluation of at least one regional lymph node [57, 62]. Postoperative complication 
rate is between 11 and 58%. Bile leakage, postresection liver failure (PLF), abdominal infection, 
and portal vein embolism are included. Perioperative mortality rate is between 1.2 and 7% [82, 
83]. In a recent French study based on 163 patients who underwent potentially curative resection 
were stratified according to the stage of disease. The 5-year survival was reported to be 32% for 
all patients; 62% for Stage I (T1 N0); 27% for Stage II (T2 N0), and 14% for Stage III (T3 N0; T1–3, 
N1). Recurrence may occur in 79% patients at 5 years, despite R0 recurrence. Local recurrence is 
the most common pattern but is also observed as intrahepatic, nodal, intraperitoneal, or distant 
metastases [82]. The median survival after recurrence is about 11.1 months in all patients except 
for those who underwent recurrence resection that is 26.7 months [84]. Mavros et al. in 2014 
published in JAMA a systematic review and meta-analysis about the prognosis for patients with 
iCCA [85]. The meta-analysis was conducted on seven studies (2132 patients), and the shorter 
overall survival was associated with larger tumor size (hazard ratio 1.09 [1.02–1.16], for each 
1 cm increment); multiple tumors (1.70 [1.34–2.02]); lymph node metastasis (2.09 [1.80–2.43]); 
vascular invasion (1.87 [1.44–2.42]); and poor tumor differentiation (1.41 [1.17–1.71]) [85].
14. Unresectable disease
The majority of patients (89%) die of tumor-related liver failure: biliary obstruction, vascular 
compromise, or a combination of both. Only 40% of patients will undergo cancer-directed 
surgery. So, a large proportion of patients could be suitable for liver-directed therapies, 
even after adjuvant chemotherapy. These options include transarterial chemoembolization 
(TACE), radioembolization (TARE), hepatic arterial infusion (HAI), percutaneous ablation, 
and external beam radiation therapy (EBRT) [86]. Which one of these is the best in a given 
scenario is yet to demonstrate because of the retrospective setting of all the studies published 
to date.
14.1. Transarterial chemoembolization (TACE)
Retrospective studies of TACE have reported a range of survival times for limited numbers of 
patients with a variety of chemotherapeutics administered. Cisplatin, doxorubicin microsphere, 
and mitomycin C alone or in combination have guaranteed an overall survival of 12.3 months 
[87]; 13 months [88]; 21.1 months [89]; and 30, 13, or 15 months, respectively [90–92].
14.2. Transarterial radioembolization (TARE)
TARE with yttrium-90 (90Y) microspheres has received the most attention by the scientific 
community. In 2015, Al-Adra et al. systematically reviewed the existing literature regarding 
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the treatment of unresectable iCCAs. Twelve studies, published between 2011 and 2013, with 
relevant data regarding TARE were analyzed. The overall weighted median survival was 
15.5 months (range: 7–22.2), and the response evaluation criteria at 3 months demonstrated 
a partial response in 28% and stable disease in 54% patients. What the most, seven patients 
were able to be downstaged to undergo surgical resection [93].
14.3. Percutaneous ablation
Percutaneous ablation by radiofrequency or microwave is generally indicated for patients 
with tumors less than 4–5 cm that are not near a segmental bile duct, liver surface, or major 
vessel. Han et al. in 2015 published a systematic review and meta-analysis about the use of 
radiofrequency ablation. Seven observational studies, comprising 84 patients, were reviewed. 
The pooled 1-year, 3-year, and 5-year survival rates were 82% (95% confidence interval [CI], 
72–90%), 47% (95% CI, 28–65%), and 24% (95% CI, 11–40%) [94]. Yu et al. in 2011 retrospectively 
evaluated the experience in treating iCCA with microwave ablation. About 15 patients with a 
mean tumor size of 3.2 ± 1.9 cm (range, 1.3–9.9 cm) were treated. The cumulative overall 6-, 12-, 
and 24-month survival rates were 78.8, 60.0, and 60.0%, respectively [95]. Treatment failure, liver 
abscess, sepsis, and needle seeding are the major complications described with both techniques.
14.4. External beam radiation therapy (EBRT)
High-dose, conformal external beam radiation therapy (EBRT) has emerged as an acceptable 
treatment for selected patients with localized, unresectable iCCA. Precise determination of 
cancer location and extent of radiotherapy targeting has been made possible by the contempo-
rary evolution of diagnostic radiology techniques. Advanced EBRT techniques (3D conformal 
radiotherapy and intensity-modulated radiotherapy) are used to deliver conformal radiation to 
the target while sparing nonmalignant tissues. Consequently, unresectable iCCA patients can 
undergo accelerated and hypofractioned regimens to deliver high-dose, ablative EBRT [96–98]. 
Tao et al. published a single-institution retrospective analysis involving 79 patients with local-
ized, unresectable iCCA treated with high-dose, conformal EBRT (35–100 Gy, median 58.05 Gy, 
in 3–30 fractions). The median overall survival was 30 months [97]. Hong et al. involved 37 
patients with localized, unresectable iCCA in a multi-institutional single-arm phase II study. 
They received hypofractionated proton beam therapy with a median dose of 58.05 Gy in 15 frac-
tions delivered daily over 3 weeks. The median and 2-year overall survival were 22.5 months 
and 46.5%, respectively; the 2-year local control rate was 94%, and most recurrences occurred at 
extrahepatic sites [98]. These outcomes formed the basis for an ongoing randomized phase III 
trial study to assess how well gemcitabine hydrochloride and cisplatin with or without radia-
tion therapy work in treating patients with localized unresectable iCCA (NCT02200042).
14.5. Hepatic arterial infusion (HAI) chemotherapy
HAI has been developed in colorectal liver metastases, but in the last few years more data are 
available for iCCA. The Memorial Sloan-Kettering Cancer Center of New York research group 
led by Kemeny and Jarnagin investigated the efficacy of HAI with floxuridine and dexameth-
asone in patients with unresectable iCCA or hepatocellular carcinoma (HCC). Thirty-four 
unresectable patients (26 iCCA and 8 HCC) were treated. Partial responses were seen in 16 
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patients (47.1%); the median survival was 29.5 months and the 2-year survival was 67% [99]. 
In 2011, they published the results of a trial in which twenty-two patients (18 iCCA and 4 
HCC) were treated by systemic (IV) bevacizumab in addition to the previously described 
HAI. Median survival was 31.1 months (CI 14.14–33.59) and progression-free survival (PFS) 
was 8.45 months (CI 5.53–11.05). The trial did not prove the improvement in outcome and was 
prematurely terminated due to increased biliary toxicity [100].
Our study group recently published the personal experience with this treatment modality. 
Between 2008 and 2012, eleven patients suffering from an unresectable iCCA underwent HAI 
chemotherapy with fluorouracil and oxaliplatin. A CT scan performed after the sixth cycle of ther-
apy revealed that 5 of them had partial hepatic response (more than 45%), 2 had stable disease, 
and 4 showed clear signs of disease progression. The average survival of the entire group was 
17.6 months. Three of the patients with partial hepatic response underwent resection and 2 had 
more than 70% tumor necrosis. The median survival of patients with liver-only disease treated 
with systemic chemotherapy, who were not submitted for resection, was 15.3 months [101].
Eventually, future randomized trials comparing systemic chemotherapy and liver directed 
therapies will be required to identify the optimal treatment modality for unresectable iCCA.
15. Chemotherapy
There is still no definitive consensus regarding the standard chemotherapy regimen to treat 
patients with locally advanced and metastatic iCCA [102]. Treatment recommendations are 
based on few phase III trial data conducted on heterogeneous patient populations, includ-
ing patients with gallbladder cancer; intrahepatic, hilar, or distal cholangiocarcinoma; and in 
some cases ampullary cancer. Furthermore, surgery for iCCA has a relevant morbidity rate 
(8–10%), which often contraindicate any adjuvant treatment [103].
The role of adjuvant chemotherapy in resected iCCA is still debated and matter of concern because 
of the recurrence rate in the liver in 50–60% of patients, in the peritoneum in about 20%, and in the 
portal lymph nodes in 20–30% [62]. Currently, few randomized trials and clinical results are avail-
able. A recent meta-analysis by Horgan et al. failed to demonstrate a significant beneficial trend 
for any adjuvant therapy over observation (HR 0.75, 95% CI 0.55–1.01; P = 0.06). Those receiv-
ing chemotherapy or chemoradiotherapy derived statistically greater benefit than radiotherapy 
alone (OR, 0.39, 0.61, and 0.98, respectively; P = 0.02). The analysis, what the most, supported 
the adjuvant role of chemotherapy or chemoradiotherapy in those with lymph node positive 
disease (OR, 0.49; P = 0.004) and R1 disease (OR, 0.36; P = 0.002) [104]. Several ongoing trials 
will clarify the role of adjuvant chemotherapy: the BILCAP study (capecitabine vs. observation—
NCT00363584), the UNICANCER trial (gemcitabine/oxaliplatin vs. observation—NCT01313377), 
and the Japanese study BCAP (gemcitabine vs. observation—NCT000000820). Until then, there 
are no definitive data to provide recommendations regarding the optimal adjuvant therapy, but 
it should be discussed in patients with high risk of recurrence: R1 and N1 stage [62, 103].
For patients with advanced stage cholangiocarcinoma not amenable to locoregional and 
surgical options, the combination of gemcitabine and cisplatin is the current first-line 
chemotherapy. In 2010, Valle et al. finally defined the standard treatment for advanced 
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cholangiocarcinoma in a phase III trial (ABC-02). This study provided concrete support for 
gemcitabine and cisplatin, demonstrating improvements for the combination compared with 
gemcitabine alone both in overall survival (11.7 vs. 8.1 months; P < 0.001) and in progression-
free survival (8.0 vs. 5.0 months; P < 0.001) [105].
Other drug combinations have been considered in first-line treatment of advanced disease: 
capecitabine/oxaliplatin, capecitabine/cisplatin, gemcitabine/capecitabine, or triplets compre-
hending fluoropyrimidine/gemcitabine/platinum compound. Also, targeted therapies have 
been investigated: cetuximab, panitumumab, and erlotinib. Overall, there are no sufficient 
evidences to support new combination therapies as first-line treatment, and no activity has 
been described for novel targeted therapies [106–114].
16. Palliation
Palliative treatment plays an important role since most CCA patients are not susceptible to 
resection and the remaining subjects undergoing surgery exhibit a high rate of recurrence. It 
tends to relieve symptoms, treat sepsis, and normalize bilirubin levels before chemotherapy 
or radiotherapy treatment. Endoscopic approach is preferable (ERCP) with plastic or metal 
stent positioning. In case of tumor localization and growth preventing ERCP, percutaneous 
approach for biliary drainage is safe and equally effective as ERCP.
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